Lantheus Medical Imaging has acquired the balance of the global rights for gadofosveset trisodium, an injectable MR angiography (MRA) blood pool imaging agent that it currently markets in the U.S. as Ablavar. Terms of the purchase were not announced.
Ablavar is indicated for use in adults with known or suspected peripheral vascular disease to evaluate aortoiliac occlusive disease.
The North Billerica, Mass.-based Lantheus purchased the global rights in a recent auction of the remaining assets of Epix Pharmaceuticals, which marketed the agent as Vasovist. The company already owns rights to Ablavar in the U.S., Canada and Australia.